BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

WEST Search History

DATE: Tuesday, February 04, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR			
L10	L9 and OmpA	10	L10
L9	P40	2242	L9
DB=USPT,PGPB; PLUR=YES; OP=OR			
L8	L5 and P40	11	L8
L7	((l5/)!.CCLS. |(Andreoni/)!.CCLS. |(and/)!.CCLS.)	0	L7
L6	L5 and P40	11	L6
L5	424/190.1	440	L5
L4	((and/)!.CCLS. |(P40/)!.CCLS. |(l1/)!.CCLS.)	0	L4
DB=USPT; PLUR=YES; OP=OR			
L3	L1 and P40	4	L3
L2	L1 and nasal delivery	200677	L2
L1	((424/190.1)!.CCLS.)	294	L1

END OF SEARCH HISTORY

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. 6416971 . 08 May 91; 09 Jul 02. Soluble single chain T cell receptors. Reinherz; Ellis L., et al. 435/69.1;. C12P021/03.

☐ 2. 6410030 . 01 Sep 00; 25 Jun 02. Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation process. Binz; Hans, et al. 424/204.1; 424/211.1 530/300 530/350 536/23.72. A61K039/12 A61K039/155.

☐ 3. 6270993 . 15 Jul 98; 07 Aug 01. VEGF-binding polypeptide. Shibuya; Masabumi, et al. 435/69.1; 435/252.3 435/254.11 435/320.1 435/325 536/23.1 536/23.4 536/23.5. C07H021/04 C12N015/00.

☐ 4. 6197929 . 11 Aug 97; 06 Mar 01. Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine. Binz; Hans, et al. 530/350; 424/184.1 424/259.1 424/278.1 424/282.1 530/300 530/825. C07K001/00 A61K038/00 A61K039/108 A61K045/00.

☐ 5. 6113911 . 04 Oct 96; 05 Sep 00. Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation method. Binz; Hans, et al. 424/211.1; 424/184.1 424/185.1 424/186.1 424/204.1 435/69.1 435/69.3 536/23.72. A61K039/155 A61K039/12.

☐ 6. 6063612 . 13 Dec 91; 16 May 00. Antiviral reagents based on RNA-binding proteins. Jayasena; Sumedha D., et al. 435/235.1; 530/320 530/325 530/826. C12N007/00 C07K014/00.

☐ 7. 5477001 . 25 Jan 93; 19 Dec 95. Recombinant DNA coding for a novel protein having .beta.-1,3-glucanase activity, bacteria containing this DNA, transformed plant cells and plants. Sass; Catherine, et al. 800/301; 435/200 435/252.3 435/414 435/416 435/418 435/419 435/69.1 435/69.8 530/370 530/378 536/23.1 536/23.2 536/23.6 800/306 800/317.3 800/322. A01H005/00 C12N009/24 C12N015/29.

☐ 8. 4673641 . 25 Jan 84; 16 Jun 87. Co-aggregate purification of proteins. George; Henry J., et al. 435/69.1; 435/261 435/320.1 435/69.3 435/69.7 435/69.8 530/412 530/418 536/23.1 536/23.4. C12P021/00 C12P021/02 C12P021/04 C12N015/00 C12N001/02 C12N001/00 C07K003/24.

☐ 9. WO 27432 A1 . 08 Nov 99. 18 May 00. USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS. BONNEFOY, JEAN-YVES, et al. A61K039/385; A61K039/39 A61P031/00 A61P035/00 A61P037/00.

☐ 10. WO 200121203 A1 EP 1218029 A1 FR 2798857 A1 AU 200075301 A BR 200014246 A . Vaccine against respiratory syncytial virus, comprises enterobacterial outer membrane protein and viral immunogen, provides protective response throughout the respiratory tract. CORVAIA, N, et al. A61K009/00 A61K039/108 A61K039/155 A61K039/385 A61K048/00 A61P031/14.

Generate Collection | Print

Terms	Documents
L9 and OmpA	10

Previous Page Next Page

☐ Generate Collection

L10: Entry 9 of 10 File: EPAB May 18, 2000

PUB-NO: WO0000027432A1
DOCUMENT-IDENTIFIER: WO 27432 A1
TITLE: USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS

PUBN-DATE: May 18, 2000

INVENTOR-INFORMATION:

NAME	COUNTRY
BONNEFOY, JEAN-YVES	FR
LECOANET, SYBILLE	CH
AUBRY, JEAN-PIERRE	FR
JEANNIN, PASCALE	FR
BAUSSANT, THIERRY	FR

INT-CL (IPC): A61 K 39/385; A61 K 39/39; A61 P 31/00; A61 P 35/00; A61 P 37/00
EUR-CL (EPC): A61K039/385; A61K039/39

ABSTRACT:

CHG DATE=20001128 STATUS=O>The invention concerns the use of an enterobacterium protein OmpA, preferably Klebsiella pneumoniae P40 protein, for specific targeting of a biologically active substance associated therewith towards antigen-presenting cells, in particular human dendritic cells. The invention also concerns the use of the OmpA protein for preparing a pharmaceutical composition for preventing and/or treating diseases, in particular cancers related to a tumour-associated antigen, autoimmune diseases or infectious diseases.

End of Result Set

☐ Generate Collection

L10: Entry 10 of 10 File: DWPI Mar 29, 2001

DERWENT-ACC-NO: 2001-257929
DERWENT-WEEK: 200251

TITLE: Vaccine against respiratory syncytial virus, comprises enterobacterial outer membrane protein and viral immunogen, provides protective response throughout the respiratory tract

INVENTOR: CORVAIA, N; GOETSCH, L ; CORVA, A N ; GOESTCH, L ; CORVAIEA, N

PRIORITY-DATA: 1999FR-0011888 (September 23, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200121203 A1	March 29, 2001	F	038	A61K039/108
EP 1218029 A1	July 3, 2002	F	000	A61K039/108
FR 2798857 A1	March 30, 2001		000	A61K039/155
AU 200075301 A	April 24, 2001		000	A61K039/108
BR 200014246 A	May 21, 2002		000	A61K039/108

INT-CL (IPC): A61 K 9/00; A61 K 39/108; A61 K 39/155; A61 K 39/385; A61 K 48/00; A61 P 31/14

ABSTRACTED-PUB-NO: WO 200121203A
BASIC-ABSTRACT:

NOVELTY - Use of an outer membrane protein A (OmpA) from an enterobacterium, or its fragment, associated with an immunogenic peptide (I) from respiratory syncytial virus (RSV) to prepare a nasal composition that induces a protective response, against RSV infection, in the upper and/or lower (lung) respiratory tract.

ACTIVITY - Antiviral.

Mice were given three intranasal doses, at 10 day intervals, of P40G2Na (a fusion protein of the 130-230 amino acid (aa) part of RSV G protein and the 344 aa P40 protein of Klebsiella pneumoniae) at 40 micro g of the G protein fragment (G2Na). The mean serum titer of G2Na-specific immunoglobulin G was about 3.3 in naive mice but 4.2 in mice presensitized by intranasal administration of K. pneumoniae. When the immunized animals were challenged with RSV-A, a reduction in viral titer, in the lung, of 2 log 10 was observed for 5 of 6 animals, and the effect was even greater for presensitized animals.

MECHANISM OF ACTION - Immune response stimulator.

USE - The method is useful for producing vaccines for prevention or treatment of RSV infections.

ADVANTAGE - OmpA potentiates the immune response to some immunogenic peptides, eliminating the need for adjuvants.

ABSTRACTED-PUB-NO: WO 200121203A
EQUIVALENT-ABSTRACTS:

CHOSEN DRAWING: Dwg.0/5

☐ Generate Collection

L3: Entry 2 of 4 File: USPT May 21, 2002

US-PAT-NO: 6391316
DOCUMENT-IDENTIFIER: US 6391316 B1

TITLE: Vaccine compositions comprising Haemophilus somnus transferrin-binding proteins and methods of use

DATE-ISSUED: May 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Potter; Andrew A.	Saskatoon			CA
Rioux; Clement	Cap-Rouge			CA
Schryvers; Anthony B.	Calgary			CA

US-CL-CURRENT: 424/256.1; 424/185.1, 424/190.1, 424/193.1, 530/350

CLAIMS:

What is claimed is:

1. A vaccine composition comprising a pharmaceutically acceptable vehicle and an isolated immunogenic H. somnus transferrin-binding protein selected from the group consisting of (a) an H. somnus transferrin-binding protein 1 having at least about 90% sequence identity to the contiguous sequence of amino acids shown at amino acid positions 1-971, inclusive, of FIG. 3 (SEQ ID NO:2), (b) an H. somnus transferrin-binding protein 1 having at least about 90% sequence identity to the contiguous sequence of amino acids shown at amino acid positions 29-971, inclusive, of FIG. 3 (SEQ ID NO:2), (c) an H. somnus transferrin-binding protein 2 having at least about 90% sequence identity to the contiguous sequence of amino acids shown at amino acid positions 1-662, inclusive, of FIG. 4 (SEQ ID NO:3), and (d) an H. somnus transferrin-binding protein 2 having at least about 90% sequence identity to the contiguous sequence of amino acids shown at amino acid positions 20-662, inclusive, of FIG. 4 (SEQ ID NO:3).

2. The vaccine composition of claim 1 wherein said transferrin-binding protein comprises the amino acid sequence shown at amino acid positions 1-971, inclusive, of FIG. 3 (SEQ ID NO:2).

3. The vaccine composition of claim 2 wherein said transferrin-binding protein comprises the amino acid sequence shown at amino acid positions 29-971, inclusive, of FIG. 3 (SEQ ID NO:2).

4. The vaccine composition of claim 1 wherein said transferrin-binding protein comprises the amino acid sequence shown at amino acid positions 1-662, inclusive, of FIG. 4 (SEQ ID NO:3).

5. The vaccine composition of claim 4 wherein said transferrin-binding protein comprises the amino acid sequence shown at amino acid positions 20-662, inclusive, of FIG. 4 (SEQ ID NO- 3).

6. The vaccine composition of claim 1 comprising an H. somnus transferrin-binding protein 1 and an H. somnus transferrin-binding protein 2.

7. The vaccine composition of claim 1 further comprising an H. somnus LppB polypeptide.

8. The vaccine composition of claim 1 further comprising an adjuvant.

9. A method of treating or preventing H. somnus infection in a mammalian subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 1.

10. A method of treating or preventing H. somnus infection in a mammalian subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 2.

11. A method of treating or preventing H. somnus infection in a mammalian subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 3.

12. A method of treating or preventing H. somnus infection in a mammalian subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 4.

13. A method of treating or preventing H. somnus infection in a mammalian subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 5.

14. A method of treating or preventing H. somnus infection in a mammalian subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 6.

15. A method of treating or preventing H. somnus infection in a mammalian subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 7.

16. A method of treating or preventing H. somnus infection in a mammalian subject comprising administering to said subject a therapeutically effective amount of a vaccine composition according to claim 8.

17. A method of producing a vaccine composition comprising:

(a) providing an isolated immunogenic H. somnus transferrin binding protein selected from the group consisting of (a) an H. somnus transferrin-binding protein 1 having at least about 90% sequence identity to the contiguous sequence of amino acids shown at amino acid positions 1-971, inclusive, of FIG. 3 (SEQ ID NO:2), (b) an H. somnus transferrin-binding protein 1 having at least about 90% sequence identity to the contiguous sequence of amino acids shown at amino acid positions 29-971, inclusive, of FIG. 3 (SEQ ID NO:2), (c) an H. somnus transferrin-binding protein 2 having at least about 90% sequence identity to the contiguous sequence of amino acids shown at amino acid positions 1-662, inclusive, of FIG. 4 (SEQ ID NO;3), and (d) an H. somnus transferrin-binding protein 2 having at least about 90% sequence identity to the contiguous sequence of amino acids shown at amino acid positions 20-662, inclusive, of FIG. 4 (SEQ ID NO:3); and

(b) combining said transferrin-binding protein with a pharmaceutically acceptable vehicle.

☐ Generate Collection

L3: Entry 3 of 4 File: USPT Feb 6, 2001

US-PAT-NO: 6183755
DOCUMENT-IDENTIFIER: US 6183755 B1

TITLE: Active proteins from Borrelia burgdorferi

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Motz; Manfred	Munchen			DE
Soutscheck; Erwin	Munchen			DE
Fuchs; Renate	Deisenhofen			DE
Wilske; Bettina	Munchen			DE
Preac-Mursic; Vera	Munchen			DE

US-CL-CURRENT: 424/234.1; 424/184.1, 424/185.1, 424/190.1, 424/278.1, 424/282.1, 514/2, 530/300, 530/350, 530/825

CLAIMS:

What is claimed is:

1. A purified protein derived from Borrelia burgdorferi wherein the protein is characterized in that it

a. elicits an immunological response from a mammal;

b. has been prepared by expression in a bacterium other than Borrelia burgdorferi;

c. is free of other proteins derived from Borrelia burgdorferi; and

d. is a protein having SEQ ID NO:11, SEQ ID NO:15, at least 10 amino acids of SEQ ID NO:11, or at least 10 amino acids of SEQ ID NO:15.

2. The purified protein of claim 1 which has SEQ ID NO:11 or at least 10 amino acids of SEQ ID NO:11.

3. The purified protein of claim 1 which has SEQ ID NO:15 or at least 10 amino acids of SEQ ID NO:15.

4. The purified protein of claim 1 which can be prepared using DNA isolated from Borrelia burgdorferi.

5. The purified protein of claim 4 which can be prepared using DNA isolated from Borrelia burdorferi (DSM No. 5662).

p-100-oligodeoxynucleotide sequence (SEQ ID NO:3),

p-100-oligodeoxynucleotide sequence (SEQ ID NO:3),

Generate Collection | Print

Search Results - Record(s) 11 through 11 of 11 returned.

☐ 11. 5549898 . 15 Apr 94; 27 Aug 96. Immunogenic anaplasma marginale surface antigens, compositions, and methods of use. McGuire; Travis C., et al. 424/269.1; 424/265.1 424/266.1 424/270.1. A61K039/00 A61K039/002 A61K039/005 A61K039/018.

Generate Collection | Print

Terms	Documents
L5 and P40	11

Previous Page Next Page